- Case report
- Open Access
Myasthenia gravis following human papillomavirus vaccination: a case report
BMC Neurology volume 18, Article number: 222 (2018)
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, occurs owing to autoantibodies against acetylcholine receptors. MG symptoms can be triggered by various vaccines. Many studies have evaluated the safety and adverse events of the human papillomavirus (HPV) vaccine. Here, we present a life-threatening case of ocular and bulbar MG symptoms after HPV vaccination and a brief literature review.
A 23-year-old woman presented with binocular diplopia, ptosis, dysarthria, and dysphagia, which occurred on the 3rd day after the second HPV vaccine administration. She was diagnosed with MG based on history, clinical features, and test results. Her symptoms deteriorated on the 3rd day after admission, and she was transferred to the intensive care unit with mechanical ventilation. On the 7th day after admission, due to discomfort in the right chest, pulmonary embolism was suspected. A tracheostomy was performed on the 14th day of mechanical ventilation. In the 4th week, the tracheostomy tube was removed; all symptoms had completely resolved at discharge. She was followed up for 5 months without recurrence or further treatment.
HPV vaccination may cause MG owing to unexpected abnormal autoimmune responses. Additional studies are needed to clarify the possible causal relationship between the HPV vaccine and neurological complications and to evaluate the safety of the vaccine.
Myasthenia gravis (MG) is an autoimmune disease that causes a neuromuscular junction disorder owing to blockage of the nicotinic acetylcholine receptor (AChR). MG may be associated with autoimmune reactions, such as autoantibodies and autoimmune responses against AChR . Furthermore, MG is related to thymus disorders and other autoimmune diseases . The human papillomavirus (HPV) vaccination was developed to prevent cervical cancer and is recommended for female individuals aged 9–26 years. In South Korea, bi- and quad-rivalent vaccines have been used; however, since 2016, the nine-valent vaccine has been used, with no serious adverse effects reported to date. Here, we present a case of MG after HPV nine-valent vaccination in a patient whose condition rapidly progressed to MG.
A 23-year-old woman with binocular vertical diplopia, bilateral ptosis (which worsened with left and down gazing), dysarthria, and dysphagia visited the outpatient department. She had received a primary HPV nine-valent vaccination 2 months prior and a second vaccination 5 days before the visit. The symptoms occurred on the 3rd day after the second vaccination. The muscular strength of her upper and lower extremities was normal, and the deep tendon reflex of both sides was normal. Her ptosis and diplopia temporarily improved with an ice pack and pyridostigmine test. The repetitive nerve stimulation (RNS) did not reveal a significant decrement in deltoid, abductor digiti minimi, flexor carpi, and orbicularis oculi muscles. The serum AChR antibody titer was 1.66 nmol/L. Other autoimmune disease tests, including rheumatoid factor and antinuclear antibody, were negative. A thyroid function test was normal, and no thymus abnormality was observed on chest computed tomography (CT).
She was diagnosed with MG, and pyridostigmine oral administration and high-dose intravenous steroid therapy were initiated. Her dyspnea became more severe on the 2nd day after admission, and oxygen saturation decreased; therefore, she received intravenous immunoglobulin therapy. Afterward, spontaneous breathing became more difficult, and the dysphagia and bilateral ptosis worsened. These symptoms were determined to demonstrate an MG crisis, and mechanical ventilation was initiated after endotracheal intubation (Fig. 1). Although muscle strength was normal at admission, the extension power of the distal fingers decreased.
On the 7th day after admission, sudden tachycardia was observed, the patient experienced persistent pressure in the right chest, and oxygen saturation decreased during mechanical ventilation. Chest CT revealed a low-density-filling defect of the pulmonary artery in the right lower lobe. Ischemic changes in the lung parenchyma and an increased D-dimer level (2199 ng/mL) were also observed. Therefore, heparin treatment was initiated owing to the possibility of pulmonary embolism. The D-dimer level decreased to within the normal range (99 ng/mL) in the 2nd week after the increase.
In the 4th week of hospitalization, the symptoms further improved such that she could walk and the AChR antibody titer decreased (0.99 nmol/L). However, right eye ptosis and binocular vertical diplopia persisted. She was discharged after the dysphagia had completely resolved. The AchR antibody titer was normal (0.05 nmol/L) at discharge. The patient has returned to daily life without symptom recurrence or further treatment.
The HPV vaccination was first approved in 2006 for preventing cervical cancer. However, in Japan, serious adverse events, such as Guillain-Barré syndrome, acute disseminated encephalomyelitis, postural orthostatic tachycardia syndrome, and complex regional pain syndrome have been reported in patients receiving the HPV vaccination, which were suspected to be associated with the HPV vaccination . The causal relationship between these adverse events and HPV vaccination has not yet been elucidated, and the underlying pathogenesis remains unclear. Studies in Japan have hypothesized that an antibody that cross-reacts with autonomic ganglia, neurons, and cardiac proteins or ß1/2-adrenergic and M2/3 muscarinic receptors could be synthesized owing to the epitope of the HPV vaccination , and that cytotoxic T cells could be activated by stimulating the antibody production by binding to acetylcholine receptors . A recent study reported a complex involving HPV and p53 pro-apoptotic tumor suppressor, and the inhibitory enzyme is degraded upon complex formation . Viral oncoprotein E6 can recognize a short leucine-rich consensus sequence within ligase E6AP, and this complex finally degrades p53. The E6 domain has two zinc ions, which maintain structural features for the interactions. Non-specific interactions of HPV with AChR may result in the complex formation and unexpected side effects of HPV, which need to be investigated.
Our patient had no problems with the primary HPV vaccination but exhibited acute bilateral ptosis, dysarthria, and dysphagia on the 3rd day after the second vaccination. She also experienced acute respiratory failure and pulmonary embolism. In our case, blood stasis owing to immobilization while in the intensive care unit could be a risk factor for pulmonary embolism. However, because venous thromboembolism was reported as an adverse event of the HPV vaccination , pulmonary embolism could occur owing to the HPV vaccination.
In our patient, MG may have been induced by the HPV vaccination as an adverse event or incidentally without an association between the two factors. Therefore, it may be difficult to suggest a strong relationship between HPV vaccination and MG outbreak. However, previous studies have reported MG occurrence after inoculation with other vaccines [8,9,10], suggesting an association between symptoms and changes in immune responses in the body following vaccination. This study summarized the studies that reported the first occurrence of MG after vaccinations based on the available literature (Table 1). Additionally, there is no absolute contraindication to the use of the HPV vaccination. Our patient developed MG after receiving the nine-valent vaccine, and the relative risk of the nine-valent vaccine is unclear.
This case report implies that the HPV vaccination may cause MG. Other neurological manifestations may occur owing to unexpected abnormal autoimmune responses such as autonomic dysfunction and pain. It is important to inform patients prior to inoculation and observe the occurrence of abnormal symptoms. Moreover, it is critical to intervene promptly and treat the patient when fatal deterioration is observed. We believe that additional studies are needed to assess the possible causal relationship between the HPV vaccine and neurological complications and to evaluate the safety of the vaccine.
Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;18(10):46.
Oosterhuis HJ. The natural course of myasthenia gravis. J Neurol Neurosurg Psychiatry. 1989;52(10):1121–7.
Kinoshita T, Abe RT, Hineno A, Tsunekawa K, Nakane S, Ikeda S. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med. 2014;53:2185–200.
Pinto LA, Castle PE, Roden RB, Harro CD, Lowy DR, Schiller JT, et al. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine. 2005;23:3555–64.
Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with iplimumab. J Clin Oncol. 2012;30:2691–7.
Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature. 2016;28;529(7587):541–5.
Slade BA. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750–7.
Takizawa T, Kojima M, Suzuki S, Osada T, Kitagawa S, Nakahara J, et al. New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin: a case report and literature review. Medicine (Baltimore). 2017;96(46):e8757.
Stübgen JP. Neuromuscular disorders associated with hepatitis B vaccination. J Neurol Sci. 2010;292(1–2):1–4.
Louzir B, Othmani S, Battikh R, Ben Abdelhafidh N, Bahri M, Taalouche L, et al. Myasthenia after hepatitis B vaccination. Therapie. 2003;58(4):378–9.
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (2017R1A1A03015876) and Ministry of Science and ICT (2017R1C1B5017293). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Availability of data and materials
All data and material supporting our findings are contained within the manuscript.
Ethics approval and consent to participate
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.
The authors declare no conflicts of interest with respect to the research, authorship, funding, and/or publication of this article.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Chung, J.Y., Lee, S.J., Shin, BS. et al. Myasthenia gravis following human papillomavirus vaccination: a case report. BMC Neurol 18, 222 (2018). https://doi.org/10.1186/s12883-018-1233-y
- Adverse event
- Human papillomavirus vaccine
- Myasthenia gravis
- Myasthenia gravis crisis